Agenus to Provide Third Quarter 2024 Financial Report and Corporate Update
Agenus Inc. (AGEN)
Last agenus inc. earnings: 3/12 07:30 am
Check Earnings Report
US:NASDAQ Investor Relations:
agenusbio.com/investors
Company Research
Source: Business Wire
LEXINGTON, Mass.--(BUSINESS WIRE)--Agenus Inc. (“Agenus”) (Nasdaq: AGEN), a leader in developing novel immunological agents to treat various cancers, today announced the Company will release its third quarter 2024 financial results before the market opens on Tuesday, November 12th, 2024. Agenus executives will host a conference call and webcast at 8:30 a.m. ET that morning to discuss the results and provide a corporate update.Conference Call:To access dial-in numbers, please register here.Conference ID: 73242A live webcast and replay of the conference call will be accessible on the company’s website at https://investor.agenusbio.com/events-and-presentations and via https://events.q4inc.com/attendee/932317413.About AgenusAgenus is a leading immuno-oncology company targeting cancer with a comprehensive pipeline of immunological agents. The company was founded in 1994 with a mission to expand patient populations benefiting from cancer immunotherapy through combination approaches, usi
Show less
Read more
Impact Snapshot
Event Time:
AGEN
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
AGEN alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
AGEN alerts
High impacting Agenus Inc. news events
Weekly update
A roundup of the hottest topics
AGEN
News
- Agenus Announces Five Presentations at ASCO GI Highlighting BOT/BAL Activity Across Colorectal and Gastric Cancers [Yahoo! Finance]Yahoo! Finance
- Agenus Announces Five Presentations at ASCO GI Highlighting BOT/BAL Activity Across Colorectal and Gastric CancersBusiness Wire
- Vaccine Adjuvants Market to Hit USD 0.96 Billion by 2029 with 6.5% CAGR | MarketsandMarkets™ [Yahoo! Finance]Yahoo! Finance
- Tanner Pharma Expands Global Access to Botensilimab and Balstilimab Through Partnership With Agenus [Yahoo! Finance]Yahoo! Finance
- Agenus Inc. (NASDAQ: AGEN) had its "neutral" rating re-affirmed by analysts at HC Wainwright.MarketBeat
AGEN
Earnings
- 11/12/24 - Miss
AGEN
Sec Filings
- 12/16/24 - Form 4
- 12/5/24 - Form 8-K
- 12/3/24 - Form 4
- AGEN's page on the SEC website